The multiple ascending dose (MAD) study analysed repeated dosing with the drug for Alzheimer’s as well as other indications with cognitive dysfunction.
Assessing the safety and tolerability of ACD856 was the primary objective of the trial.
According to the latest findings from an exploratory assessment, ACD856 was found to boost electroencephalogram (EEG) activity in the brain.
Additionally, a noticeable variation was reported before and prior to the dosing.
The latest data along with prior results indicate that the drug could cross the blood-brain barrier as well as reach and trigger neural pathways in the brain, to offer a positive impact on cognition.
This MAD study is the third of its kind trial of the company to analyse ACD856.
ACD856 is the lead candidate of the company in the NeuroRestore platform.
It is being developed as a symptom-relieving drug for ailments that affect cognitive ability, such as Alzheimer’s.
As reported priorly, ACD856 had demonstrated robust safety and tolerability in the SAD and MAD studies.
AlzeCure Pharma CSO Johan Sandin said: “These new data are very promising and show that the substance reaches and activates neural pathways in the brain, whose normal function is disrupted in diseases such as Alzheimer’s.”
In prior preclinical research, ACD856 as well as the other therapies in the NeuroRestore platform could induce various key signalling systems and signalling substances in the brain such as Brain Derived Neurotrophic Factor and Nerve Growth Factor, to boost cognition.
In the latest preclinical findings, these drugs also showed possible neuroprotective and disease-modifying abilities.